Abstract 298P
Background
Adenoid cystic carcinoma (ACC) of the breast is a rare subtype of breast cancer that is characterized by more favorable outcomes than extramammary ACC. Its rarity makes the establishment of standardized treatment protocols challenging. This study aimed to develop a machine learning (ML)-based prognostic model that improves the accuracy of survival rate predictions for patients with ACC.
Methods
The SEER database provided the data used for this study’s analysis (2000–2020). Patients who met any of the following criteria were excluded: diagnosis not confirmed by histology, previous history of cancer or other concurrent malignancies, or unknown data. To identify prognostic variables, we conducted Cox regression and constructed prognostic models using five ML algorithms to predict the 5-year survival. Patient records were randomly divided into training (70 %) and validation (30 %) sets. A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of the ML models.
Results
The study population comprised 1212 patients. The median patient age was 60 years, and the median tumor size was 1.9 cm. The largest racial group was white (79.5 %). Furthermore, most cases were localized (95.1%), T1 (56.2%), and N0(96.4%). The most common type of surgery performed was partial mastectomy (74.8%). Analysis of the therapeutic options revealed significantly different survival rates. While surgery + RT had a 94.9% overall 5-year survival rate, surgery alone had a rate of 91%. For surgery + CTX, the survival rate was 83.5% and 80.1% for surgery + CTX + RT. The corresponding cancer specific survival rates were 68.5%, 63.5%, 75%, and 70.8%, respectively. The ML models demonstrated strong predictive capabilities, with random forest classifier performing the best. ML identified that the most contributing factors were age, followed by the N component of the AJCC stage and ER status.
Conclusions
ML approaches provide superior predictive performance compared with traditional statistical methods. The developed models can significantly aid personalized treatment planning and improve the clinical outcomes of patients with ACC.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
323P - SPEN: Unraveling breast cancer's genetic symphony — Prognostic significance and therapeutic insights
Presenter: Sameer Emeish
Session: Poster session 14
324P - Application of advanced machine learning techniques to improve prognosis in primary breast angiosarcoma
Presenter: Haya Kamal
Session: Poster session 14
Resources:
Abstract
325P - The clinical validity of histological grade in neoadjuvant treated breast cancer
Presenter: Sanna Steen
Session: Poster session 14
326P - Exploratory analysis of the association of systemic inflammation and breast cancer recurrence in the Optitrain randomised controlled trial
Presenter: Marlene Rietz
Session: Poster session 14
327P - Monitoring over time of pathological complete response to neoadjuvant chemotherapy in breast cancer patients through an ensemble vision transformers-based model
Presenter: Maria Colomba Comes
Session: Poster session 14
328P - Real-world evidence (RWE) of effectiveness and safety of TCHP regimen: INSIGHT-HER2BC trial interim results
Presenter: Daur Meretukov
Session: Poster session 14
329P - RANK/RANKL, ERBB-2: A putative dual targeting strategy in RANK+/Her2+ breast carcinomas patients
Presenter: Michalis Karamouzis
Session: Poster session 14
330P - Randomized phase II study of neoadjuvant chemotherapy with denosumab compared to chemotherapy alone in hormonal receptor-positive, HER2-negative premenopausal breast cancer patients
Presenter: Shereef Elsamany Mohammed
Session: Poster session 14
331P - Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer
Presenter: Mingxia Jiang
Session: Poster session 14
332P - Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab plus nab-paclitaxel followed by epirubicin/cyclophosphamide for TNBC: A phase II TREND trial
Presenter: yingying Xu
Session: Poster session 14